From JPMA From the "JPMA Press Conference
1. Summary of "The Necessity of Industrial Policy in the Pharmaceutical Industry
We believe that it is necessary to promote measures against infectious diseases from normal times as part of the COVID-19 convergence and the reinforcement of measures against new infectious diseases that will come in the future. Furthermore, we believe that healthy growth of the domestic pharmaceutical industry is essential for the creation of domestically produced vaccines and therapeutics, and that it is necessary to promote industrial policy by positioning the pharmaceutical industry as a fundamental and key industry of the country.
Now, Japan is trying to promote DX (Digital Transformation) and move toward the realization of "Society 5.0" and "Data-driven Society". We believe that the life science sector, in addition to the digital and green sectors, should by all means be raised as a field that will play a role in the post-corona economic recovery.
Japan Pharmaceutical Manufacturers Association
Chairman, Joji Nakayama
Summary of "JPMA Policy Proposal 2021
COVID-"JPMA Policy Proposal 2021" outlines the vision of the JPMA industry. First of all, it is necessary to establish a system that can predictably achieve both "promotion of innovation" and "sustainability of universal health coverage" even under the severe financial situation of the social security system. We would also like to establish a system in which the various values of pharmaceuticals and their value based on the evidence newly established after marketing are appropriately evaluated, and in which companies proactively explain their value and gain a high degree of acceptance and trust from the public.
JPMA and its member companies will continue to do their utmost to save as many patients suffering from illnesses as possible, even a day sooner, and to spread a brighter future for both patients and the world. To this end, we will strive to gain the understanding of all sides, as an environment in which innovation can be created and innovation can be properly evaluated is necessary.
(From JPMA Newsletter May 2021 No.203 Top News)
Japan Pharmaceutical Manufacturers Association (JPMA)
JPMA was founded in 1968 as an organization of R&D-oriented pharmaceutical companies with the aim of contributing to the improvement of health and welfare of people around the world through research and development of ethical drugs for use in hospitals, clinics, and other medical institutions.
JPMA is dedicated to the realization of patient-participatory medicine through activities to deepen understanding of pharmaceuticals and policy recommendations for the sound development of the pharmaceutical industry.
As a member organization of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), JPMA is engaged in global activities in cooperation with other organizations to address issues related to medicine and pharmaceuticals around the world.
Japan Pharmaceutical Manufacturers Association Aims to Contribute to Society through the Development of New Drugs